Women's Health & Gynecology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study

This study is exploring a new non-invasive blood test for pregnant individuals to assess fetal genetic conditions like Down syndrome and other chromosomal differences. By using circulating fetal cells in the blood, this test aims to provide earlier and safer risk assessment without the need for invasive procedures. If successful, it could reduce anxiety and risks for many families during pregnancy.

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

This clinical trial is looking at whether tranexamic acid can help reduce bleeding during second trimester dilation and evacuation procedures, which are a type of abortion care. By potentially lowering blood loss, the medication could make these procedures safer and reduce the need for further medical intervention. This study focuses on pregnant adults between 18 and 24 weeks gestation.

Developing and Implementing HPV SCREENED

This study is testing a new way to screen for cervical cancer using HPV self-sampling kits in emergency departments for women who may not regularly get screened. Making screening easier and more accessible could help catch cervical cancer earlier and improve outcomes. The trial will enroll women who have historically been under-screened, aiming to reach those who might otherwise miss timely care.

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

This research uses electronic health record tools to encourage more women to get genetic testing for hereditary breast and ovarian cancer risks. Identifying genetic risk can lead to earlier monitoring and preventive care, potentially improving long-term health. This study has already been completed with over 1200 participants and offers insight into how digital tools can support patient care.

Signatera Assessment in Early-Stage Endometrial Cancer

This trial evaluates a blood test that uses circulating tumor DNA to help guide treatment decisions for women with early-stage endometrial cancer. The test could help some patients avoid radiation therapy by closely monitoring cancer recurrence risk. Participants receive regular blood tests and follow-up visits over two years to track their health.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.